Thursday, January 16, 2025 7:36:10 AM
The size of an initial New Active Substance (NAS) Marketing Authorisation Application (MAA) submitted to the Medicines and Healthcare products Regulatory Agency (MHRA) can vary widely depending on the complexity of the product and the data included. However, it is generally a substantial document with the following typical characteristics:
Page Count
• The total page count for a complete dossier often ranges from 10,000 to 50,000 pages or more. This includes all modules of the Common Technical Document (CTD), which is the standard format for regulatory submissions.
Breakdown by Modules
1. Module 1: Administrative and Product Information
• Usually a few hundred pages, depending on the number of annexes and administrative forms.
• Includes the application form, product information, and labeling.
2. Module 2: Common Technical Document Summaries
• Typically 100–300 pages, summarizing the quality, safety, and efficacy data.
3. Module 3: Quality/CMC (Chemistry, Manufacturing, and Controls)
• Can range from a few thousand to tens of thousands of pages, depending on the complexity of the manufacturing process and specifications.
4. Module 4: Non-Clinical Study Reports
• Generally 1,000–10,000 pages, depending on the number of studies conducted and the extent of non-clinical data required.
5. Module 5: Clinical Study Reports
• Can range from several thousand to tens of thousands of pages. This module often represents the bulk of the dossier due to the detailed clinical trial data.
Factors Influencing the Size
• Type of Drug: Complexity of manufacturing, formulation, and delivery mechanism.
• Clinical Trial Program: The number and scope of clinical studies included.
• Regulatory Requirements: Specific data requirements from MHRA or other health authorities.
• eCTD Formatting: The use of electronic submissions via eCTD can result in a variable page count due to formatting, appendices, and linked documents.
Let me know if you’d like a more detailed breakdown or specific guidance on preparing such an application!
- Above is ChatGPT reply
Page Count
• The total page count for a complete dossier often ranges from 10,000 to 50,000 pages or more. This includes all modules of the Common Technical Document (CTD), which is the standard format for regulatory submissions.
Breakdown by Modules
1. Module 1: Administrative and Product Information
• Usually a few hundred pages, depending on the number of annexes and administrative forms.
• Includes the application form, product information, and labeling.
2. Module 2: Common Technical Document Summaries
• Typically 100–300 pages, summarizing the quality, safety, and efficacy data.
3. Module 3: Quality/CMC (Chemistry, Manufacturing, and Controls)
• Can range from a few thousand to tens of thousands of pages, depending on the complexity of the manufacturing process and specifications.
4. Module 4: Non-Clinical Study Reports
• Generally 1,000–10,000 pages, depending on the number of studies conducted and the extent of non-clinical data required.
5. Module 5: Clinical Study Reports
• Can range from several thousand to tens of thousands of pages. This module often represents the bulk of the dossier due to the detailed clinical trial data.
Factors Influencing the Size
• Type of Drug: Complexity of manufacturing, formulation, and delivery mechanism.
• Clinical Trial Program: The number and scope of clinical studies included.
• Regulatory Requirements: Specific data requirements from MHRA or other health authorities.
• eCTD Formatting: The use of electronic submissions via eCTD can result in a variable page count due to formatting, appendices, and linked documents.
Let me know if you’d like a more detailed breakdown or specific guidance on preparing such an application!
- Above is ChatGPT reply
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
